BridgeBio Oncology Therapeutics ratios data for the quarter ended Jun 2026. These financial ratios cover 11 quarters of results from Dec 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Efficiency | |||||||||||
| Assets AverageAssets Avg. | 93.93M | 188.70M | 191.10M | 178.32M | 179.99M | 196.53M | 341.09M | 466.59M | 433.01M | 397.18M | |
| Invested CapitalInvested Cap. | -115.57M | -178.15M | -199.95M | -227.63M | 510.69M | 411.63M | 373.00M | ||||
| Leverage & Solvency | |||||||||||
| Debt Ratio | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Valuation | |||||||||||
| Price to EarningsP/E | 482.80 | 238.30 | 231.05 | 141.07 | -0.00M | 896.95 | -14.69 | -17.99 | -12.09 | -10.14 | |
| Price to BookP/B | -2.87 | -2.96 | -2.72 | -1.24 | -2.34 | -2.91 | 1.42 | 1.90 | 1.50 | 1.89 | |
| Enterprise Value | 367.93M | 422.27M | 431.84M | 66.59M | 467.69M | 661.85M | 254.11M | 355.58M | 306.06M | 384.77M | |
| EV to EBIT | -0.01M | -0.00M | -21.96 | -3.04 | -20.21 | -21.99 | -5.17 | -8.19 | -6.63 | -6.39 | |
| EV to EBITDA | -0.01M | -0.00M | -21.96 | -3.04 | -20.21 | -21.99 | -5.17 | -8.19 | -6.63 | -6.39 | |
| Market Capitalization | 369.78M | 424.09M | 433.63M | 222.22M | 468.66M | 662.51M | 722.40M | 781.04M | 558.33M | 610.48M | |
| Price to FCFP/FCF | -598.35 | -0.01M | -11.02 | -14.79 | -23.72 | -28.16 | -24.99 | -15.85 | -16.14 | -13.29 | |
| EV to FCF | -595.36 | -0.01M | -10.98 | -4.43 | -23.67 | -28.13 | -8.79 | -7.22 | -8.85 | -8.38 | |
| EV to CFO | -595.36 | -0.01M | -10.98 | -4.43 | -23.86 | -28.41 | -8.83 | -8.42 | -8.52 | -8.67 | |
| Return Ratios | |||||||||||
| Return on Capital Employed [ROCE]ROCE | -26.31% | -36.40% | -48.88% | -40.70% | -33.79% | -43.33% | -57.58% | ||||
| Return on Assets [ROA]ROA | -18.68% | -30.89% | -43.71% | -34.59% | -30.38% | -38.52% | -50.09% |